ABBV vs COP: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and ConocoPhillips — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C High Quality
VS
ConocoPhillips · Energy
$122.55
-21.4% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value (+4.5%). ABBV trades at a lower forward P/E (14.9x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ABBV COP
Current Price $208.05 $122.55
Fair Value Estimate $217.50 $96.36
Upside to Fair Value +4.5% -21.4%
Market Cap $367.9B $149.8B
Forward P/E 14.9x 19.3x
EV / EBITDA 16.7x 5.8x
Price / Sales 6.1x 2.5x
Price / FCF 20.9x 8.9x
Revenue Growth YoY +8.6% +7.5%
Gross Margin 83.7% 24.6%
Operating Margin 34.7% 19.6%
Return on Equity -129.24% 12.39%
Dividend Yield 3.2% 3.41%
FCF Yield 4.78% 10.9%
Analyst Consensus Buy Buy
Investment Thesis
ABBV — AbbVie Inc.
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
COP — ConocoPhillips
ConocoPhillips is the largest U.S. independent exploration and production company, operating approximately 2.4 million barrels of oil equivalent per day across its Lower 48, Alaska, Canada, and international segments. The company completed its transformative $22.5 billion Marathon Oil acquisition in late 2024 and is on track for $2 billion in cost synergies by the end of 2026. Full-year 2025 reve…
Accumulation Zones
Metric ABBV COP
Zone Low $163.13 $72.27
Zone High $184.88 $81.91
In Buy Zone? No No
← ABBV Research    COP Research →    All Research